Your browser doesn't support javascript.
Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia.
Frontera, Jennifer A; Boutajangout, Allal; Masurkar, Arjun V; Betensky, Rebecca A; Ge, Yulin; Vedvyas, Alok; Debure, Ludovic; Moreira, Andre; Lewis, Ariane; Huang, Joshua; Thawani, Sujata; Balcer, Laura; Galetta, Steven; Wisniewski, Thomas.
  • Frontera JA; New York University Grossman School of Medicine, New York, New York, USA.
  • Boutajangout A; New York University Grossman School of Medicine, New York, New York, USA.
  • Masurkar AV; New York University Grossman School of Medicine, New York, New York, USA.
  • Betensky RA; New York University School of Global Public Health, New York, New York, USA.
  • Ge Y; New York University Grossman School of Medicine, New York, New York, USA.
  • Vedvyas A; New York University Grossman School of Medicine, New York, New York, USA.
  • Debure L; New York University Grossman School of Medicine, New York, New York, USA.
  • Moreira A; New York University Grossman School of Medicine, New York, New York, USA.
  • Lewis A; New York University Grossman School of Medicine, New York, New York, USA.
  • Huang J; New York University Grossman School of Medicine, New York, New York, USA.
  • Thawani S; New York University Grossman School of Medicine, New York, New York, USA.
  • Balcer L; New York University Grossman School of Medicine, New York, New York, USA.
  • Galetta S; New York University Grossman School of Medicine, New York, New York, USA.
  • Wisniewski T; New York University Grossman School of Medicine, New York, New York, USA.
Alzheimers Dement ; 18(5): 899-910, 2022 05.
Article in English | MEDLINE | ID: covidwho-1620097
ABSTRACT

INTRODUCTION:

Neurological complications among hospitalized COVID-19 patients may be associated with elevated neurodegenerative biomarkers.

METHODS:

Among hospitalized COVID-19 patients without a history of dementia (N = 251), we compared serum total tau (t-tau), phosphorylated tau-181 (p-tau181), glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), ubiquitin carboxy-terminal hydrolase L1 (UCHL1), and amyloid beta (Aß40,42) between patients with or without encephalopathy, in-hospital death versus survival, and discharge home versus other dispositions. COVID-19 patient biomarker levels were also compared to non-COVID cognitively normal, mild cognitive impairment (MCI), and Alzheimer's disease (AD) dementia controls (N = 161).

RESULTS:

Admission t-tau, p-tau181, GFAP, and NfL were significantly elevated in patients with encephalopathy and in those who died in-hospital, while t-tau, GFAP, and NfL were significantly lower in those discharged home. These markers correlated with severity of COVID illness. NfL, GFAP, and UCHL1 were higher in COVID patients than in non-COVID controls with MCI or AD.

DISCUSSION:

Neurodegenerative biomarkers were elevated to levels observed in AD dementia and associated with encephalopathy and worse outcomes among hospitalized COVID-19 patients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Alzheimer Disease / Cognitive Dysfunction / COVID-19 Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Alzheimers Dement Year: 2022 Document Type: Article Affiliation country: Alz.12556

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Alzheimer Disease / Cognitive Dysfunction / COVID-19 Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Alzheimers Dement Year: 2022 Document Type: Article Affiliation country: Alz.12556